CALGB/SWOG 80405 [2], Fire-3 [3] and PEAK [4] randomised controlled trials have all firmly established bevacizumab (VEGFR-inhibitor), cetuximab and panitumumab, (EGFR inhibitors) as first-line therapies in addition to FOLFOX/FOLFOXIRI in the management of patients with metastatic colorectal cancer. The gene discussed is EGFR; the disease is metastatic colorectal cancer.